T. Rowe Price Associates
ENZY

T. Rowe Price Associates’s Enzymotec Ltd ENZY Stock Holding History

T. Rowe Price Associates’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-166,445
Closed -$458K – 2657
2017
Q3 		$458K Sell
166,445
-108,000
-39% -$1.07M ﹤0.01% 2124
2017
Q2 		$713K Hold
274,445
– – ﹤0.01% 1917
2017
Q1 		$774K Sell
274,445
-25,197
-8% -$213K ﹤0.01% 1889
2016
Q4 		$741K Hold
299,642
– – ﹤0.01% 1888
2016
Q3 		$2.1M Sell
299,642
-4,803
-2% -$38.5K ﹤0.01% 1529
2016
Q2 		$986K Hold
304,445
– – ﹤0.01% 1712
2016
Q1 		$1.07M Hold
304,445
– – ﹤0.01% 1688
2015
Q4 		$1.16M Hold
304,445
– – ﹤0.01% 1652
2015
Q3 		$1.07M Hold
304,445
– – ﹤0.01% 1686
2015
Q2 		$985K Sell
304,445
-68,445
-18% -$628K ﹤0.01% 1750
2015
Q1 		$533K Hold
372,890
– – ﹤0.01% 1955
2014
Q4 		$556K Sell
372,890
-53,984
-13% -$392K ﹤0.01% 1922
2014
Q3 		$85K Buy
+426,874
New +$4.6M ﹤0.01% 2488

Other funds holding ENZY

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DG
Delek Group Herzliya, Israel $2.59B AUM 1.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GH
GAM Holding Zurich, Switzerland $1.57B AUM 25.73% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
CRA
Circle Road Advisors New York $27.7M AUM 35.85% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's ENZY Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Enzymotec Ltd (ENZY) in Q4 2017, closing a stake of 166,445 shares — an estimated $458K sold.

T. Rowe Price Associates first reported a position in ENZY in Q3 2014 and held it in 13 quarters. The position peaked at $2.1M in Q3 2016. 37 funds tracked by Wall St. Rank hold ENZY as of Q4 2017.

  • T. Rowe Price Associates reported no remaining Enzymotec Ltd position as of Q4 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 166,445 Enzymotec Ltd shares in Q4 2017, an estimated $458K.
  • T. Rowe Price Associates first reported a position in Enzymotec Ltd in Q3 2014 and held it in 13 quarters.
  • T. Rowe Price Associates's Enzymotec Ltd position peaked at $2.1M in Q3 2016.
  • 37 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.